Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug allergy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Drug allergy. Displaying page 3 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002451-21 Sponsor Protocol Number: M16-048 Start Date*: 2016-12-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 in Adult Subjects with Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis in adults
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) IE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-002967-23 Sponsor Protocol Number: M-17923-30 Start Date*: 2022-01-27
    Sponsor Name:Almirall, S.A.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients ...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000229-24 Sponsor Protocol Number: RD.06.SPR.201593 Start Date*: 2021-02-23
    Sponsor Name:Galderma S.A.
    Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Moderate-to-severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000285-42 Sponsor Protocol Number: D3256C00001 Start Date*: 2020-12-31
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36–week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Sev...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000487-28 Sponsor Protocol Number: VO72.12 Start Date*: 2013-08-20
    Sponsor Name:STALLERGENES SA
    Full Title: A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma
    Medical condition: house dust mite-associated allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004870 10020419 House dust mite allergy LLT
    14.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Ongoing) PL (Completed) BG (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001198-15 Sponsor Protocol Number: R668-AD-1334 Start Date*: 2015-01-06
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003254-24 Sponsor Protocol Number: R668-AD-1224 Start Date*: 2015-03-12
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Moderate to severe atopic dermatitis (AD).
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) IT (Completed) HU (Completed) NL (Completed) LV (Prematurely Ended) BE (Completed) PL (Completed) ES (Completed) RO (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002653-35 Sponsor Protocol Number: R668-AD-1424 Start Date*: 2016-01-14
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolera...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BE (Completed) GB (Completed) NL (Completed) SK (Completed) AT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004724-39 Sponsor Protocol Number: GT-10 Start Date*: 2006-02-13
    Sponsor Name:ALK-Abelló A/S
    Full Title: A randomised, parallel-group, open, controlled Phase III trial assessing the treatment compliance with GRAZAX in subjects with seasonal grass pollen induced rhinoconjunctivitis
    Medical condition: IgE mediated allergy (hay fever, rhinoconjunctivitis) to grass pollen (Timothy grass, Phleum pratense) with or without asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039085 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004300-34 Sponsor Protocol Number: DRM06-AD06 Start Date*: Information not available in EudraCT
    Sponsor Name:Dermira, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000049-56 Sponsor Protocol Number: GS29250 Start Date*: 2015-05-29
    Sponsor Name:F. Hoffmann-la roche Ltd
    Full Title: A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequat...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) FI (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000133-22 Sponsor Protocol Number: V00114 CP 304 2A Start Date*: 2008-04-28
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Estudio de la eficacia y seguridad del antihistamínico V0114CP 2.5 mg en el tratamiento de la rinitis alérgica estacional. Estudio aleatorizado, doble ciego, de tres ramas y grupos paralelos, que i...
    Medical condition: Demostrar la eficacia de un tratamiento de 2 semanas con el antihistamínico V0114CP 2,5 mg frente a placebo en la reducción de síntomas de la rinitis alérgica estacional
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) EE (Completed) BE (Completed) LT (Completed) PL (Completed) HU (Completed) DE (Completed) IT (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2015-000762-65 Sponsor Protocol Number: CAIN457ADE01T Start Date*: 2015-07-09
    Sponsor Name:Technische Universität München, School of Medicine, represented by Dean
    Full Title: Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum
    Medical condition: Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and redu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037635 Pyoderma gangrenosum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002096-42 Sponsor Protocol Number: 6057-PR-PRI-188 Start Date*: 2012-09-18
    Sponsor Name:LETI Pharma GmbH
    Full Title: Biological Standardization of Ambrosia elatior Allergen Extract Determination of the Biological Activity in HEP units. An Open Monocenter Study.
    Medical condition: Allergy to Ambrosia elatior (ragweed)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10036664 Prick test LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001650-25 Sponsor Protocol Number: CASM981C2440 Start Date*: 2005-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of El...
    Medical condition: Mild to moderate facial atopic dermatitis (AD), in children
    Disease: Version SOC Term Classification Code Term Level
    M15 10003639
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004301-28 Sponsor Protocol Number: DRM06-AD17 Start Date*: Information not available in EudraCT
    Sponsor Name:Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company
    Full Title: AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002601-26 Sponsor Protocol Number: EFC16823 Start Date*: 2024-02-11
    Sponsor Name:Sanofi K.K
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel-group study to evaluate the efficacy, safety and pharmacokinetics of dupilumab compared to placebo in Japanese patients with a...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001625-79 Sponsor Protocol Number: AK002-018 Start Date*: 2022-11-21
    Sponsor Name:Allakos Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequatel...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003361-37 Sponsor Protocol Number: C5041005 Start Date*: 2023-03-06
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRI...
    Medical condition: Moderate-to-Severe Atopic Dermatitis with a History of Prior Systemic Treatment Failure
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-018562-23 Sponsor Protocol Number: 6078-PG-PSC-169 Start Date*: 2010-09-15
    Sponsor Name:LETI Pharma GmbH
    Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivi...
    Medical condition: Allergic rhinitis and/or allergic rhinoconjunctivitis with or without intermittent asthma.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10001728 Allergic rhinoconjunctivitis LLT
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001723 Allergic rhinitis LLT
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) BG (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 00:53:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA